Hengrui Medicine: Clinical trial approval for injectable SHR-9803 drug

People’s Financial News, March 11 — Hengrui Medicine (600276) announced on March 11 that recently the company received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration for injectable SHR-9803, and clinical trials will commence soon. This drug is a Class 1 therapeutic biological product that can activate anti-tumor immune activity to achieve the purpose of tumor treatment.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin